2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

101. Red Cells and Erythropoiesis, Excluding Iron: Poster III

Program: Poster Abstract Session
Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Molecular Testing, Profiling, Treatment Considerations, Combination Therapy, Therapy Sequence, Biological Therapies, Antibody Therapy, Non-Biological Therapies, Artificial Intelligence (AI), Machine Learning, Biological Processes, Apoptosis, Pathogenesis, CHIP, Genomics, Hematopoiesis, Immune Mechanism, Metabolism, Molecular Biology, Clinical Practice (Health Services and Quality), Clinical Guidelines, Quality of Care, Diseases, Bone Marrow Failure Syndromes, Genetic Disorders, Hemoglobinopathies, Immunology, Autoimmune Disorders, Autoimmune Hemolytic Anemia, Infectious Diseases, Other Pathogens, Metabolic Disorders, Research, Fundamental Science, Translational Research, Clinical Research, Clinical Trials, Real-World Evidence, Registries, Study Population, Human, Adult, Elderly, Young Adult, Animal Model
PAPER

4629 low-dose stanozolol for non-severe aplastic anemia: Clinical outcomes and whole-exome sequencing-derived molecular markers for response stratification

Rudan Zheng, Xinru Jia2, Tianye Zhou3, Qi Liu4, Yingying Shen5, Yun Zhang II, MMed6, Xiawan Yang7, Yuhong Zhou8, Dijiong Wu, MD,PhD9
1 The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou, Zhejiang, China
2 The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou, Zhejiang, China
3 The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou, Zhejiang, China
4 The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou, Zhejiang, China
5 The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou, Zhejiang, China
6 The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou, Zhejiang, China
7 The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou, Zhejiang, China
8 The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou, Zhejiang, China
9 The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou, Zhejiang, China

Background: Clinical evidence supporting low dose stanozolol-based therapy in the treatment of nonsevere aplastic anemia (NSAA) remains limited. In this study, we evaluated the efficacy and safety of this regimen, and conducted an exploratory analysis of clinical and molecular correlates of hematologic response.

Methods: We conducted a retrospective cohort study of 78 patients with NSAA treated at a single center from August 2022 through January 2026. All patients were treated with low dose stanozolol-based therapy, with stanozolol dosed at a maximum of 2 mg twice daily and dose reductions tailored to hematologic response and tolerability. Preexisting immunosuppressive agents and thrombopoietin receptor agonists were tapered or discontinued, with no additional therapies that may confound the primary efficacy assessment initiated during the observation period. We collected baseline characteristics including age, sex, prior therapies, transfusion dependence, and hematologic profiles. Hematologic responses were assessed at 1, 3, and 6 months. The primary endpoint was the 6-month overall response rate (ORR), defined as complete response (CR) plus partial response (PR). Original sequencing reports were available for 65 patients, 47 of whom also had germline variant analysis. Group comparisons were performed using Fisher exact or Mann-Whitney U tests.

Results: Among the 78 patients, the median age was 45.5 years (range, 6–87), with 45 males (57.7%) and 33 females (42.3%). According to prior cyclosporine A (CsA) exposure, 38 patients had experienced treatment failure, relapse, or intolerance following a standard CsA course, while 40 had not received an adequate standard CsA regimen. At baseline, 18 patients (23.1%) were transfusion dependent and 60 (76.9%) were transfusion independent. The ORR significantly increased from 46.2% at 1 month to 65.4% at 3 months and 79.5% at 6 months (P < 0.001). At 6 months, 12 (15.4%) patients achieved CR, 50 (64.1%) achieved PR, and 16 (20.5%) were non-responders. Among 62 responders, the median time to durable response was 39.5 days (interquartile range, 21.8–73.0). The 6-month ORR did not differ by prior CsA treatment status (78.9% [30/38] vs 80.0% [32/40]; P = 1.000) or baseline transfusion status (83.3% [15/18] vs 78.3% [47/60]; P = 0.751). Adverse events occurred in 10 patients (12.8%), including menstrual irregularities in 6 of 33 female patients (18.2%), liver function test elevations ≥ 2-fold the upper limit of normal in 3 patients (3.8%), and acne in 1 patient (1.3%). All these adverse events were mild in severity and well tolerated by affected patients. No grade ≥ 3 or serious treatment-related adverse events were documented.

Of the 47 patients with germline variant analysis, 15 (31.9%) carried at least one report-classified pathogenic/likely pathogenic variant, all located in Fanconi anemia/DNA repair–associated genes. Most were monoallelic variants in recessive disorder genes and insufficient to establish an inherited bone marrow failure syndrome diagnosis. Patients harboring these variants had numerically higher ORR (88.9% vs 70.0%; P = 0.142) and erythroid response rates (72.2% vs 35.7%; P = 0.072). Among 65 patients who underwent genetic testing, non-W515L MPL variant carriers had a significantly lower ORR (2/6 [33.3%] vs 50/59 [84.7%]; P = 0.012). No platelet response was observed in carriers (0/6 vs 28/56 [50.0%] among noncarriers; P = 0.028), along with a smaller median platelet count increment (1.5 vs 17.0 × 10^9/L; P = 0.025). High-confidence acquired clonal alterations were detected in 6 of 65 patients (9.2%). The 6-month ORR was 50.0% (3/6) in patients with such alterations versus 83.1% (49/59) in those without, showing a non-significant trend toward inferior response (P = 0.089).

Conclusions: Low dose stanozolol-based therapy was associated with progressive hematologic improvement with acceptable short-term safety profile, including among patients with prior CsA failure or intolerance and those classified as transfusion dependent at baseline. Patients carrying Fanconi/DNA repair associated germline variants showed favorable albeit non-significant trends in both ORR and erythroid response. MPL variants showed the most consistent exploratory association with impaired response, particularly platelet response, whereas patients with acquired clonal alterations had a numerically lower ORR. These findings require validation in larger, independent cohorts.

Rudan Zheng: No relevant conflicts of interest to declare.